Archana Jastorff

Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.

T. Schwarz, B. Cheuvart, Luis Rivera, 2018, Vaccine.

Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study

F. Struyf, N. Folschweiller, Naveen Karkada, 2020, Asia-Pacific journal of clinical oncology.

Safety of AS04‐HPV‐16/18 vaccine in Chinese women aged 26 years and older and long‐term protective effect in women vaccinated at age 18–25 years: A 10‐year follow‐up study

Xun Zhang, Naveen Karkada, D. Borys, 2022, Asia-Pacific journal of clinical oncology.

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.

G. Dbaibo, M. van der Wielen, Archana Jastorff, 2018, Vaccine.

Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.

J. Ziegler, H. Marshall, R. Booy, 2019, The Pediatric infectious disease journal.

MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.

P. Chanthavanich, Luis Rivera, M. van der Wielen, 2018, Vaccine.